Literature DB >> 7522632

Tumor necrosis factor alpha (TNF alpha) downregulates c-kit proto-oncogene product expression in normal and acute myeloid leukemia CD34+ cells via p55 TNF alpha receptors.

E Khoury1, C Andre, S Pontvert-Delucq, B Drenou, C Baillou, M Guigon, A Najman, F M Lemoine.   

Abstract

Tumor necrosis factor alpha (TNF alpha), as a modulator of hematopoiesis, interacts with many growth factor receptors, such as interleukin-3, granulocyte-macrophage colony-stimulating factor (CSF), and granulocyte-CSF receptors. Here, we studied the interactions between TNF alpha and the stem cell factor (SCF) receptor, c-kit, in normal CD34+ hematopoietic progenitors and their leukemic counterpart, ie, acute myeloid leukemic (AML) CD34+ cells coexpressing c-kit antigen. The results showed that (1) incubation of normal bone marrow mononuclear cells with 200 U/mL rhTNF alpha for 20 hours induced a diminution of 31.2% +/- 5.2% of CD34+ cells coexpressing c-kit; (2) the same decrease was observed using purified CD34+ cells and, furthermore, their proliferative response to SCF was inhibited by 31.5% +/- 7.3% after exposure to TNF alpha; (3) similar experiments performed on CD34+ c-kit+ AML cells from 11 patients gave comparable results. Further analysis at the mRNA level indicated that TNF alpha decreased c-kit mRNA transcripts. Moreover, using monoclonal antibodies against the two types of TNF alpha receptors, p75 and p55, we showed that the downregulation of c-kit proto-oncogene product by TNF alpha, on normal and leukemic CD34+ cells, was exclusively mediated by the TNF alpha p55 receptor. Therefore, we conclude that TNF alpha acts as a downregulator of the SCF receptor expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522632

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.

Authors:  Yuki Kagoya; Akihide Yoshimi; Keisuke Kataoka; Masahiro Nakagawa; Keiki Kumano; Shunya Arai; Hiroshi Kobayashi; Taku Saito; Yoichiro Iwakura; Mineo Kurokawa
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

2.  Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.

Authors:  Anamika Bose; Jennifer L Taylor; Sean Alber; Simon C Watkins; Jorge A Garcia; Brian I Rini; Jennifer S Ko; Peter A Cohen; James H Finke; Walter J Storkus
Journal:  Int J Cancer       Date:  2011-05-25       Impact factor: 7.396

3.  The effect of human cytomegalovirus on the formation of CFU-MK in vitro.

Authors:  Junxia Yao; Sanjun Song; Lihua Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

Review 4.  Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies.

Authors:  Leopold Ohler; Klaus Geissler; Wolfgang Hinterberger
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

5.  High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model.

Authors:  Rieneke van de Ven; Sue Ellen Verbrugge; Anneke W Reurs; Hetty J Bontkes; Erik Hooijberg; Gerrit Jansen; Rik J Scheper; George L Scheffer; Tanja D de Gruijl
Journal:  Cancer Immunol Immunother       Date:  2011-03-24       Impact factor: 6.968

Review 6.  Regulation of hematopoietic and leukemic stem cells by the immune system.

Authors:  C Riether; C M Schürch; A F Ochsenbein
Journal:  Cell Death Differ       Date:  2014-07-04       Impact factor: 15.828

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.